Nordic Nanovector’s lead clinical-stage candidate is Betalutin ®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026.
https://ih.advfn.com/stock-market/stock-news/83949837/nordic-nanovector-financial-calendar-2021

